Article by Nasdaq via Cannabis Life Network
Emerald Health Therapeutics, Inc. is announcing its new nanoemulsion-based Fast Action Spray product line, an important step in Emerald’s Cannabis 2.0 strategy and a unique offering in the Canadian cannabis marketplace. This unique formulation offers notable advantages over existing formats of cannabis consumption in terms of convenience and predictability of consumption. The product line will consist of CBD and THC cannabinoids mixed with specific terpenes and flavorings. The first product is planned for launch in June.
Emerald’s first product is a CBD 12.5 mg/mL + myrcene combination that it expects to launch for medical users in June. Additional products include a CBD 15 mg/mL lemon + limonene combination and a THC 15 mg/mL citrus + limonene combination, expected to be launched in July into adult-use channels. Emerald has chosen to add specific all-natural terpenes to its nanoemulsion product line: myrcene has been shown to have anti-inflammatory, analgesic, and anxiolytic properties; limonene has been shown to have anti-inflammatory, analgesic, antioxidant, antidepressant and immunostimulating attributes*. Emerald is also developing “flavour-masked” versions, which will have significantly less cannabis flavour. All of the Fast Action Spray products will be packaged in 15 mL bottles.
“This is a game-changing new product category for the Canadian cannabis marketplace,” said Riaz Bandali, President & CEO of Emerald. “Our nanoemulsion product line offers convenience, predictability, no odour, and attractive value relative to the amount of absorbable active ingredient. We believe these products offer both medical and adult-use consumers a tremendously advantageous choice compared to inhaled or edible products to achieve desired outcomes from cannabis. We are pleased with the interest from cannabis distribution boards in multiple provinces that we have experienced about this new product and look forward to soon launching this line.”
Most non-smoked or non-vaped cannabis products including oils and other emulsions must be processed through our digestive tract before the active cannabinoids and terpenes can enter the bloodstream and provide their desired effects. The result is often hours-long delay in the onset of the product’s effects. Being mixed with other food products also unpredictably alters the onset and effects of the ingredients from use to use. Furthermore, the path of administration and molecular characteristics of these products result in very low levels of bioavailability, or absorption, of the active ingredients – many of the medically important molecules travel from the gut straight to the liver, where they’re broken down and inactivated before they can have their desired effect. This is inefficient and expensive.